Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables - Net (2023 - 2025)

Historic Receivables - Net for Krystal Biotech (KRYS) over the last 3 years, with Q4 2025 value amounting to $127.4 million.

  • Krystal Biotech's Receivables - Net rose 2165.14% to $127.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $127.4 million, marking a year-over-year increase of 2165.14%. This contributed to the annual value of $127.4 million for FY2025, which is 2165.14% up from last year.
  • Krystal Biotech's Receivables - Net amounted to $127.4 million in Q4 2025, which was up 2165.14% from $129.6 million recorded in Q3 2025.
  • Over the past 5 years, Krystal Biotech's Receivables - Net peaked at $129.6 million during Q3 2025, and registered a low of $9.3 million during Q3 2023.
  • For the 3-year period, Krystal Biotech's Receivables - Net averaged around $93.3 million, with its median value being $104.0 million (2024).
  • In the last 5 years, Krystal Biotech's Receivables - Net skyrocketed by 94441.82% in 2024 and then tumbled by 138.05% in 2025.
  • Krystal Biotech's Receivables - Net (Quarter) stood at $42.0 million in 2023, then surged by 149.16% to $104.7 million in 2024, then rose by 21.65% to $127.4 million in 2025.
  • Its Receivables - Net was $127.4 million in Q4 2025, compared to $129.6 million in Q3 2025 and $111.4 million in Q2 2025.